Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes

Diabetes Care

Volumn 36, Issue 2, 2013, Pages 245-250

  Kaku, Kohei ^a   Araki, Takahiro ^b   Yoshinaka, Ryoji ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; GLIMEPIRIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; PROINSULIN; TAK 875; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACKACHE; CHOLECYSTITIS; CLINICAL ASSESSMENT; COLON POLYP; CONSTIPATION; CONTROLLED STUDY; CONTUSION; DIABETIC DIET; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK FRACTURE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; JAPANESE; KINESIOTHERAPY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOFURANS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; SULFONES; TREATMENT OUTCOME;

EID: 84873835561     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0872     Document Type: Article

References (11)

1. Haber EP, Ximenes HM, Procópio J, Carvalho CR, Curi R, Carpinelli AR. Pleio-tropic effects of fatty acids on pancreatic b-cells. J Cell Physiol 2003;194:1-12
2. Stoddart LA, Smith NJ, Milligan G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1,-2, and-3: pharmacology and pathophysiological func-tions.Pharmacol Rev 2008;60:405-417
3. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic b cells through GPR40. Nature 2003;422:173-176
4. Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic b-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009;58:1067-1076
5. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008;57:2432-2437
6. Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2010;1:290-294
7. Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and phar-macodynamic properties of the GPR40 agonist TAK-875: results from a doubleblind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2012;52:1007-1016
8. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 2012;14:271-278
9. Kashiwagi A, Kasuga M, Araki E, et al.; Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diab Invest 2012;3: 39-40
10. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1403-1411
11. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of in-cretin secretion. Diabetes 2008;57:2280-2287